-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Continuing Conversations with the Speakers on Harnessing T cells in Therapy of Hematologic Malignancy

PhD Trainee  Ticketed Session
Program: Continuing Conversations with the Speakers
Sunday, December 6, 2015: 11:15 AM-12:15 PM
W303, Level 3 (Orange County Convention Center)
Chair:
Steven Z. Pavletic, MD, MS, NIH, NCI

Disclosures:
No relevant conflicts of interest to declare.
Speakers:
Dirk Hans Busch, MD, Technische Universitat Munchen , Michel Sadelain, MD, PhD, Memorial Sloan Kettering Cancer Center and Crystal L. Mackall, MD, National Cancer Institute/National Institutes of Health

Disclosures:
Busch: STAGE cell therapeutics: Other: I was share holder of STAGE cell therapeutics, a company that was recently bought by Juno therapeutics. . Sadelain: Juno Therapeutics: Consultancy , Equity Ownership , Other: Co-Founder, stockholder , Patents & Royalties: Licensed patents on CARs . Mackall: Juno: Patents & Royalties: CD22-CAR .
Speaker

Dirk Hans Busch, MD

Institute for Medical Microbiology, Immunology and Hygiene, Technische Universitat Munchen, Munich, Germany
Speaker

Michel Sadelain, MD, PhD

Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
Speaker

Crystal L. Mackall, MD

Pediatric Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, MD
See more of: Continuing Conversations with the Speakers
<< Previous Session | Next Session >>